Skip to content

Summer Harvest Adventure: A Garden-based Obesity Prevention Program for Children Residing in Low-resource Communities

Summer Harvest Adventure: A Garden-based Obesity Prevention Program for Children Residing in Low-resource Communities

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05367674
Acronym
SHA
Enrollment
192
Registered
2022-05-10
Start date
2017-03-01
Completion date
2022-03-31
Last updated
2026-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Obesity

Keywords

obesity, youth, garden, diet, produce

Brief summary

The objective of this study is to implement and test the efficacy of the "Summer Harvest Adventure," a comprehensive garden-based behavioral, social, and environmental intervention for children (ages 8-11 years) residing in low-resource communities.

Detailed description

The investigators will conduct a 2-arm randomized controlled trial designed to determine the efficacy of a multifaceted obesity prevention and lifestyle intervention in low-resource children and parent/adult caregiver (PAC) called "Summer Harvest Adventure." A total of 240 children (ages 8-11 years) will be randomized to the garden-based intervention (SHA) or an enhanced control group (MSP). Summer Harvest Adventure includes: 1) remote and group coaching using a focused motivational interviewing approach; 2) weekly fruit, vegetable, and herb harvesting to increase summer food access; and 3) group education for children and their families in a social setting. Assessments for both groups will be collected at orientation held one week prior to the intervention (week 0), and immediately following the completion of the intervention (week 10) by trained personnel that are blinded to participants' treatment arm assignment.

Interventions

BEHAVIORALSummer Harvest Adventure

Biobehavioral intervention focusing on nutrition and lifestyle behaviors.

BEHAVIORALMy Summer Plate (MSP)

My Summer Plate (MSP)

Sponsors

Ohio State University
Lead SponsorOTHER
Nationwide Children's Hospital
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Masking description

Clinical assessments for both groups (intervention and control) will be conducted by trained personnel that are blinded to participants' treatment arm assignment.

Intervention model description

Phase 2 prospective randomized controlled trial

Eligibility

Sex/Gender
ALL
Age
8 Years to 11 Years
Healthy volunteers
Yes

Inclusion criteria

* Children 8-11 years of age (as of June 1) from assenting and consenting families * English-speaking families that agree to participate; 3) residents of SNAP-eligible communities in Franklin County, Ohio.

Exclusion criteria

* Inability to functionally participate in harvesting; accommodations can be implemented in the future for children with special needs * Communication difficulties (e.g. severe developmental delay) * Lack of transportation to weekly classes or harvesting activities * Non-English speakers; because coaching and classroom-based education are all conducted in English, we will of necessity restrict to English-speakers only during this phase

Design outcomes

Primary

MeasureTime frameDescription
Produce IntakeBaseline and 10 weeksChange in fruit and vegetable intake as assessed by dermal skin carotenoid scores using Raman Spectroscopy (Pharmanex NuSkin Biophotonic Scanner model S3). Dermal skin carotenoid scores range 10,000-85,000, with higher scores indicating higher skin carotenoid levels.

Secondary

MeasureTime frameDescription
WeightBaseline and 10 weeksChange in weight will be recorded with a precision of 0.1 kilogram (kg)
Family EngagementBaseline and 10 weeksChange in family engagement as assessed by the Expressed Emotion Adjective Checklist. The Expressed Emotion Adjective Checklist (EEAC) is a self-reported measure of expressed emotions. Twenty items are summed to a total score (range 20-140); higher scores indicate more positive expressed emotion (better outcome).
Blood PressureBaseline and 10 weeksChange in blood pressure will be measured using non-invasive brachial blood pressure assessment using oscillometric technology (automated devices) to obtain blood pressure readings
HeightBaseline and 10 weeksChange in standing height will be measured to the nearest 1 mm using a standardized fixed stadiometer with a vertical backboard and moveable headboard
BMI PercentileBaseline and 10 weeksBMI will be calculated using weight (kg) divided by the square of height (m). BMI-for-age percentile growth charts will be used to measure the size and growth patterns of children in the study

Countries

United States

Participant flow

Recruitment details

COVID-19 required shut down of study in Years 2 & 3

Pre-assignment details

SNAP-eligible adolescent between the ages of 8-11 + caregiver. Data was collected only for the children enrolled, thus enrollment numbers represent unique participants (i.e., children enrolled in study).

Baseline characteristics

Characteristic
Age, Categorical
<=18 years
192 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
6 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
89 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
100 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
92 Participants
Region of Enrollment
United States
96 Participants
Sex: Female, Male
Female
53 Participants
Sex: Female, Male
Male
39 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 960 / 96
other
Total, other adverse events
0 / 960 / 96
serious
Total, serious adverse events
0 / 960 / 96

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 1, 2026